Eye Diseases Clinical Trial
Official title:
Comparison of Manual Versus Automated Choroidal Thickness Measurements Using Swept-source Anterior Segment Optical Coherence Tomography
NCT number | NCT05211089 |
Other study ID # | 17300719 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 1, 2021 |
Est. completion date | January 1, 2022 |
Verified date | January 2022 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The choroid, which is located between the retina and the sclera, is a connective tissue layer that is densely packed with blood vessels and is responsible for supplying oxygen and nutrients to the retina's periphery. One of the primary functions of the choroid is to support the metabolism of the retinal pigment epithelium (RPE). It is implicated in the pathogenesis of a variety of retinal disorders, including age-related macular degeneration, polypoidal choroidal vasculopathy, central serous chorioretinopathy, and high myopia-associated chorio retinal atrophies. Because choroidal alteration has a fundamental role in the development and progression of these diseases, choroidal thickness provides comprehensive information to physicians. For the study of the choroid, researchers have used ultrasound, magnetic resonance imaging MRI, and Doppler laser, but these methods have limited utility due to a lack of resolution. Contrary to this, indocyanine green (ICG) angiography provides valuable clinical information but does not provide cross-sectional images of the choroid for in vivo research studies. Optical coherence tomography (OCT) has gained in popularity in clinical and experimental ophthalmology over the last decade as a way to acquire detailed, three-dimensional images of the retina . Imaging the entire choroid, on the other hand, has proven to be more difficult due to the significant decline in signal strength beyond the RPE prompted by the pigment in the RPE and choroid and light scattering in the vasculature. The development of improved depth imaging (EDI) by Spaide et al. opened the door to quantitative choroid assessment. Choroid imaging is currently possible using one of two optical coherence tomography (OCT) techniques: (1) spectral-domain (SD) OCT utilizing standard light sources using EDI, and (2) swept-source (SS) OCT using a long wavelength light .A 1 m-band light source is used in SS-OCT, which penetrates deeper into the retino choroidal tissues and so optimizes the resolution. To better visualize retinal and choroidal changes, SS-OCT can concurrently display a focused image of both the retina and the choroid. This renders it an accurate technology for assessing choroidal thickness. Such findings of choroidal thickness changes revealed that the choroid and choroidal thickness may be important attributes in the evaluation of ocular pathology. To properly understand the scientific value of these potential choroidal thickness variations, it would appear that comprehensive and systematic normative values for choroidal thickness are fundamental.
Status | Completed |
Enrollment | 80 |
Est. completion date | January 1, 2022 |
Est. primary completion date | December 1, 2021 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Normal adult volunteers Exclusion Criteria: - Eyes with chorioretinal or vitreoretinal diseases - History of intraocular surgery - Glaucoma. - Systemic diseases or conditions that could affect retinal or choroidal thickness, - Pregnant women |
Country | Name | City | State |
---|---|---|---|
Egypt | Faculty of Medicine | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Choroidal thickness | Manual and automated measurement of choroidal thickness | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05414994 -
Assessment of the Ocular Microbiome in Health and Disease
|
||
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Completed |
NCT02811692 -
Study for Collection of Aflibercept Data in Routine Practice
|
||
Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT04799704 -
Tear Film SARS-nCoV-2 Detection in Symptomatic and Pauci-symptomatic Patients.
|
||
Recruiting |
NCT05876689 -
Swept Source OCT Imaging With the DREAM VG-OCT
|
||
Active, not recruiting |
NCT04123626 -
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
|
Phase 1/Phase 2 | |
Recruiting |
NCT04150432 -
Correlation Between Exhaled Propofol Concentration With Plasma Concentration in Children
|
N/A | |
Not yet recruiting |
NCT05550740 -
Repeated Low-Level Red-Light Therapy for Shortening Axial Length
|
N/A | |
Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Terminated |
NCT01225146 -
Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
|
Phase 1 | |
Completed |
NCT00333203 -
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
|
Phase 3 | |
Not yet recruiting |
NCT05565547 -
Multimodal Equipment for Teleophthalmology Assessment (META)
|
||
Recruiting |
NCT05158699 -
Effectiveness of Periocular Drug Injection in CATaract Surgery
|
Phase 3 | |
Recruiting |
NCT06451172 -
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
|
Early Phase 1 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06070467 -
Holistic Mixed Approaches to Capture the Real Life of Children With Rare Eye Diseases
|
||
Completed |
NCT02946879 -
Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
|